49.34

1.48% -0.748

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $49.34, with a volume of 792.74K. It is down -1.48% in the last 24 hours and up +1.77% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$50.09

Open:

$49.86

24h Volume:

792.74K

Relative Volume:

0.24

Market Cap:

$21.93B

Revenue:

$2.38B

Net Income/Loss:

$1.32B

P/E Ratio:

27.71

EPS:

1.7806

Net Cash Flow:

$897.24M

1W Performance:

-0.06%

1M Performance:

+1.77%

6M Performance:

+31.46%

1Y Performance:

+51.94%

1-Day Range:

$49.29

$49.96

1-Week Range:

$49.21

$50.47

52-Week Range:

$31.97

$50.47

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1107)

Industry

Biotechnology (615)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	49.36	22.01B	2.38B	1.32B	897.24M	1.7806
VRTX Vertex Pharmaceuticals Inc	424.58	109.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	704.19	76.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	784.06	48.20B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	300.02	40.31B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.28	33.13B	5.36B	287.73M	924.18M	2.5229

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	UBS	Neutral → Buy
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

09:24 AM

Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX) - simplywall.st

09:24 AM

Apr 30, 2026

Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock - MarketBeat

Apr 30, 2026

Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock - Investing.com India

Apr 30, 2026

Royalty Pharma Insider Sold Shares Worth $1,731,840, According to a Recent SEC Filing - marketscreener.com

Apr 30, 2026

Royalty Pharma (RPRX) CFO sells 34,791 shares under 10b5-1 plan - Stock Titan

Apr 30, 2026

Apr 29, 2026

Royalty Pharma Plc Hits New 52-Week High of $50.24 - Markets Mojo

Apr 29, 2026

Royalty Pharma Plc Experiences Revision in Its Stock Evaluation Amid Strong Performance - Markets Mojo

Apr 29, 2026

Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat

Apr 29, 2026

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Apr 29, 2026

Mitsubishi UFJ Trust & Banking Corp Increases Position in Royalty Pharma PLC $RPRX - MarketBeat

Apr 29, 2026

Apr 28, 2026

Royalty Pharma signs $500M co-development agreement with J&J - MSN

Apr 28, 2026

Affiliate sales disclosed for RPRX (NASDAQ: RPRX) in Form 144 filing - Stock Titan

Apr 28, 2026

Royalty Pharma prices $2B senior unsecured notes - MSN

Apr 28, 2026

Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat

Apr 28, 2026

Royalty Pharma stock hits 52-week high at $50.24 - Investing.com

Apr 28, 2026

Teacher Retirement System of Texas Lowers Position in Royalty Pharma PLC $RPRX - MarketBeat

Apr 28, 2026

Apr 27, 2026

Royalty Pharma declares $0.235 dividend - MSN

Apr 27, 2026

Royalty Pharma in $500M R&D funding collaboration with J&J - MSN

Apr 27, 2026